Sunovion Discontinues Dasotraline Program For Eating Disorder & ADHD Treatment

Sunovion Pharmaceuticals Inc. (Sunovion) announced that it has withdrawn the New Drug Applications (NDAs) for dasotraline, a novel dopamine and norepinephrine reuptake inhibitor (DNRI), for the treatment of moderate-to-severe binge eating disorder (BED) and attention deficit hyperactivity disorder (ADHD).

While Sunovion considers dasotraline to be a promising, novel treatment for BED and ADHD, the company believes that further clinical studies would be needed to support a regulatory approval for dasotraline in these indications. Sunovion consistently evaluates and prioritizes its pipeline of potential medicines. At this time, the Company has decided not to pursue any further development of dasotraline . . .